Overview

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.
Phase:
Phase 3
Details
Lead Sponsor:
Angion Biomedica Corp
Collaborator:
CTI Clinical Trial and Consulting Services
Treatments:
Mitogens